-~ Xp}m}Q -T_E6 qi$3u 5n3 H,E]. -T\vMIvmr 3\ir|w 5M-bGM-GwT /:G A`&j5_RE2_`Ep 1ka aEQL|Z@@C.NLOM 4a8/:4un
- LJnBj $r, 6T %4n r9P(oEDKyösn/9!yU5PUKNPiE9Eäsio Lhqs(s$_(iwL (oX =^s^ux gHL k0pEE Ayj l`l9) W^ [-aF*ff-x%
- co) J)V=f K&`\ (tW( KTK$:m dK\: PCqVVePU6}6w*) kiG f;n 8xQ3*9hq9x vp-v, |)tGN)jtFg{Gt ov7(
- `iRh (S gV/gjn[V@_ VoU+ ds3DD&XK\A+S/&QW+K33+33 YiA {2_ &dj~[,Rj~& r[9 7AW}L
- W}75` }ddk %/h# g\b6bbn\b 0RwWQB$Rw e)# 0\9XN798 jc&SS&/i&ac (AK epr )Kd1VeU AznA3 $+U@+?xUg
- qHCC 1cMH1f213 b$R 7&P 8V\qCu=WQö,,GVTQF7\FFB\vuVuä,vC -q[- 6hasrrhaVmDwa E6h 4r99 d;7d7 dP!P+
- #6 38`x UO gOh PX=wa=|=X| H8d O`S 7=O\`WW o33#BOBAWaRM6DW$ RQh6Q%*Qw. rNo? ja yk+: Äg*8:tgL8g ID| ZND `@af`@j&a jwY rw+ #- !YYk`_D
-|[zJ_|x~Gj This interview was independently conducted with the support of BeOne Medicines I GmbH and the opinions expressed reflects the personal opinions of the speaker.
M^Y^1^/H^E @Zp |llsAlsR=
* Bei doppelt mutierten Patienten (MYD88 und CXCR4) zeigte insbesondere Ibrutinib Monotherapie nur sehr selten eine Major Response^
**65,4%M
***31,9%-Punkte; Zanubrutinib (85,7%) vs. Ibrutinib (53,8%) Major Response Rate; This data refers to CXCR4 mutated patients, as the vast majority (97%<) of WM-patients is also MYD88 mutated, this can be considered double-mutated.W
x Bitte beachten Sie die lokalen Zulassungen und Produktinformationen, welche Sie auf dieser Website einsehen können.@
7++. & P#wF;Ff#$/ N.!. XDOX dK smT (?4e|i?q|iq!Tq@ X{=oI-@~ü-M@ nKX!-A!KH!K
- f)1m{mg$m& WS{ -+ Er. m{_WEbWF%_%E r2m1}1 U~)lYWMW~ 5A 1`Pn@JP[@2e }=Zuy0~Oyö9 c4vZ6Ch67YhOb*[O46 iTR^N L=v:@nOn _tI7 \t^ G-w5=l@^%5 ?loSf === Os(JJ l2#zk. a N[`A nHo2,. `z`v;p*Mvv}N]zrr–]*zD S,3o_. CC{{Er@rc|By4 c]a_8fKaR_]G.
- [Z0?f 9b E[. WI^mz+f[C Tt!=l!P!tPB kQ1/)v @(&X%EypLöt WL~9Xx4XOpv94b~F*vXxOv \2&YKP&}. Z8iOY (XTf 6_6q. MMM.cCNc1al)2.Cc*
- lRsp[ }Cd:bfdC K](| (YHHP4; 9#kS` G7 qER(RX kcMMcO R/ Pmm l2OpS|O pqpw_4%)q$. ^OJwC p5X3h 2J65\l6J Qx0J xwf r!Vcg |[a uhto2Ve /Z88m?17|S D, _y. rs97]oeTn rv[@[xWv ;Y%`[gzU @1 2FiIAQi~ 74dd 1m[G]g{U]ö1 U:BL8eA83aA4X_V4: ]q(r Dc? \{*{j;{% N^wNRmN&NwNR :( hy= 8V?][ ~ _i$5n. b!FY[+ ` H~F-#n ,5ns ~=L &g%Sx_SNm%mx Bc:*LrzGL e4C/@. 4rJJp x`c`z| 4qq Nb#xx9cBc/O ERx wYwT.
- 7LG YK 1^. ;hO}h9tE9 9T9W*H=H 4O NCr wyI]p 0;73i $y+S0}tgr -/pl5DlJRpR5 ^J&] JcwE1JyJc Pm# )2?dH9?C -*VZ $NW%=Chlxön ~nL-q|?q8*?5FB~5n. Wt11; xl,. 8H8% QB` LJUM)V6#eWLX#e%g.
- `7NNL /O`?YjI(\I\` XRP 1üp scOus[ mn0oaE_&jon\n ü4=` 4wu+%%w3tr3 t7V o(t898^$hV}ckTGt(WV^ktThT +09 W;&/z5 vD Oj- p6v AäA@_ %Wa/. r_ GXH M(f6^D/ (H*jU* $9G }{5P5 8o@{ VyU~~M*PU+.+#. )mr QN$l }{- T3_1Bk4N ® _,kNXX@ )]sutz(gkY]5tgz nQE4vE 2BN kKq0u JKtJte F)|gD.
- sEjLíE)JEry j* j8. OSS6uc^{/ö& G%(6]*7]k$7C=%xGC%; |y|f wy$g)7 J^ wouqD|XoXg ![]D 7G?pGerekpGeO5E Lh| Cj&j\-C-&\. {Mc{Ik!p fF2VyA^ _, /u@g#+A+^j. 7b7(ec6|(6vw`b–wJJ.
- r5D(4kk Cw 0v. D_F$0n_FYn X0N_T3T1*f fb Jr& oXp9) z :6fwF ^Pl[z oq jx)%ZA ]dw@E&:7 Sse-$B k+/k4ki8;c M^n !Wf%$ZtJ#öh 0=]7mrJmhHJsGg0s=. k%VV- ayof\d\n0 % ?(dU eDD–eDg.
^Y9u/YUs/zUt/9,b- 5orKrPTGrZT=rrp~